The reverse split is a technical measure to maintain Nasdaq listing, not a fundamental change. The larger risk is the overhang from the S-3 registration of ~350M shares for resale by former Marea stockholders and PIPE investors, which could pressure the stock post-split. Monitor trading volume and any insider selling patterns.
Drugs in focus
LSTA drug pipeline →MAR001/005
● Neutral Named in this press release- Impact
- Phase
- Phase 2b
- Time to market
- At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
- Next catalyst
- None dated
What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 19 $0.9100entry
- T+1 · 2d ago −1.22%α +2.42% · $0.8989
- T+5 · in 5d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lisata Therapeutics announced a 1-for-15 reverse stock split, effective November 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The split reduces outstanding shares from ~10.8M to ~0.7M and follows a recent S-3 shelf registration that registered ~350M shares for resale by selling stockholders, creating potential overhang.
Key Facts
- Reverse stock split ratio of 1-for-15, effective November 23, 2026
- Outstanding shares reduced from ~10.8M to ~0.7M
- Stockholders approved the split at the November 9, 2026 annual meeting
- No fractional shares will be issued; cash paid in lieu
- S-3 shelf filed 7 days ago registers ~350M shares for resale by selling stockholders from the Marea acquisition and PIPE
- Company will not receive proceeds from the S-3 resale
Financial Impact
Reduction in share count from ~10.8M to ~0.7M; no change in market cap or ownership percentages
Risk Factors
- Potential selling pressure from S-3 registered shares (350M shares for resale)
- Low market cap ($11M) and low liquidity amplify price moves
- Reverse split alone does not address business fundamentals; clinical-stage pipeline with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3406677 |
Track record
21 reports on LSTA
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
- Nov 19, 20262d ago Press Release Neutral 4/10 Viewing Entry $0.9100 settles Feb 18
- Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
- Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
- Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
- Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
- Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers